澳大利亚制药行业向专业医学协会领导人的支付情况：关注心血管疾病和糖尿病。
Pharmaceutical industry payments to leaders of professional medical associations in Australia: Focus on cardiovascular disease and diabetes.
机构信息
PhD, Postdoctoral Fellow, Charles Perkins Centre, School of Pharmacy, Faculty of Medicine and Health, University of Sydney, NSW.
Student, Charles Perkins Centre, School of Pharmacy, Faculty of Medicine and Health, University of Sydney, NSW.
出版信息
Aust J Gen Pract. 2020 Mar;49(3):151-154. doi: 10.31128/AJGP-08-19-5041.
BACKGROUND AND OBJECTIVES
Pharmaceutical industry interactions with professional medical associations have come under scrutiny, yet industry ties among the leadership of these associations are often overlooked. The aim of this study was to investigate pharmaceutical industry payments to leaders of Australian diabetes or cardiovascular associations, and general associations serving doctors who manage these conditions.
METHOD
Payments were identified using publicly available industry transparency reports (October 2015 to April 2018).
RESULTS
Overall, 48/197 (24.4%) leaders received payments, predominantly for speaker (51.4%) and advisory board (25.3%) engagements. The proportion of paid leaders was higher for diabetes- and cardiovascular-specific associations (72.7% and 41.2%, respectively) than for general associations (7.6%).
DISCUSSION
These findings raise concerns about industry influence on clinical practice and policy.
背景和目的
制药行业与专业医学协会的互动受到了严格审查，但这些协会领导层之间的行业联系往往被忽视。本研究旨在调查澳大利亚糖尿病或心血管协会以及管理这些疾病的医生的普通协会的领导接受制药业支付的情况。
方法
使用公开的行业透明度报告（2015 年 10 月至 2018 年 4 月）确定支付情况。
结果
总体而言，197 名领导人中有 48 人（24.4%）获得了报酬，主要是演讲（51.4%）和顾问委员会（25.3%）参与。糖尿病和心血管特定协会的付费领导人比例（分别为 72.7%和 41.2%）高于普通协会（7.6%）。
讨论
这些发现引起了人们对行业对临床实践和政策的影响的关注。
Zotero 插件